Oxidation of p-aminophenols and formal radical cyclization onto benzene rings: Formation of benzo-fused nitrogen heterocycles

Organic Letters

Volumn 7, Issue 1, 2005, Pages 23-26

  Fletcher, Stephen P ^a   Clive, Derrick L J ^a   Peng, Jianbiao ^a   Wingert, David A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPHENOL; AMINE; BENZENE; IODINE DERIVATIVE; KETONE DERIVATIVE; METHANOL; NITROGEN;

AROMATIZATION; ARTICLE; CHEMICAL PROCEDURES; CHEMICAL REACTION; CYCLIZATION; GRIGNARD REACTION; OXIDATION; REACTION ANALYSIS;

EID: 12344322897     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol047977j     Document Type: Article

References (28)

1. (a) For mechanistic discussion, see: Beckwith, A. L. J.; Bowry, V. W.; Bowman, W. R.; Mann, E.; Parr, J.; Story, J. M. D. Angew. Chem., Int. Ed. 2004, 43, 95-98.
2. (b) Beckwith, A. L. J.; Storey, J. M. D. J. Chem. Soc., Chem. Commun. 1995, 977-978.
3. (c) Crich, D.; Hwang, J.-T. J. Org. Chem. 1998, 63, 2765-2770.
4. (d) Cf. Crich, D.; Sannigrahi, M. Tetrahedron 2002, 58, 3319-3322.
5. (a) Axon, J.; Boiteau, L.; Boivin, J.; Forbes, J. E.; Zard, S. Z. Tetrahedron Lett. 1994, 35, 1719-1722.
6. (b) Liard, A.; Quiclet-Sire, B.; Saicic, R.; Zard, S. Z. Tetrahedron Lett. 1997, 38, 1759-1762.
7. (c) Cholleton, N.; Zard, S. Z. Tetrahedron Lett. 1998, 39, 7295-7298.
8. (d) Hoang-Cong, X.; Quiclet-Sire, B.; Zard, S. Z. Tetrahedron Lett. 1999, 40, 2125-2126.
9. (e) Ly, T.-M.; Quiclet-Sire, B.; Sortais, B.; Zard, S. Z. Tetrahedron Lett. 1999, 40, 2533-2536.
10. (f) Kaoudi, T.; Quiclet-Sire, B.; Seguin, S.; Zard, S. Z. Angew. Chem., Int. Ed. 2000, 39, 731-733.
11. (g) Quiclet-Sire, B.; Sortais, B.; Zard, S. Z. J. Chem. Soc., Chem. Commun. 2002, 1692-1693.
12. (h) Quiclet-Sire, B.; Zard, S. Z. J. Chem. Soc., Chem. Commun. 2002, 2306-2307.
13. (i) Zard, S. Z. Angew. Chem., Int. Ed. Engl. 1997, 36, 672-685.
14. (a) Menes-Arzate, M.; Martínez, R.; Cruz-Almanza, R. Muchowski, J. M.; Osornio, Y. M.; Miranda, L. D. J. Org. Chem. 2004, 69, 4001-4004.
15. (b) For other leading references, see ref 4.
16. Clive, D. L. J.; Fletcher, S. P.; Liu, D. J. Org. Chem. 2004, 69, 3282-3293.
17. For example, see the following. Kinase inhibitors: Smithkline Beecham, WO 2004043379, 2004. Histamine H3 receptor antagonists: Eli Lilly, WO 2004026837, 2004. 2,3-Oxidosqualene-lanosterol cyclase inhibitors: Hoffmann-La Roche, WO 2002050041, 2002. Growth hormone release promoters: Sumimoto Pharmaceuticals, JP 11292894, 1999. Treatment for dementia: U.S. Department of Health and Human Services, WO 2002048150, 2002. Dopamine D4 receptors: H. Lundbeck A/S, WO 9828293, 1998. Estrogen receptor modulators: Eli Lilly, WO 2002094788, 2002.
18. Ma, D.; Cai, Q.; Zhang, H. Org. Lett. 2003, 5, 2453-2455.
19. Klapars, A.; Huang, X.; Buchwald, S. L. J. Am. Chem. Soc. 2002, 124, 7421-7428.
20. (a) Yoon, T.; Shair, M. D.; Danishefsky, S. J. Tetrahedron Lett. 1994, 35, 6259-6262.
21. (b) Shair, M. D., Yoon, T. Y.; Mosnie, K. K.; Chou, T. C.; Danishefsky, S. J. J. Am. Chem. Soc. 1996, 118, 9509-9525.
22. (c) Myers, A. G.; Tom, N. J.; Fraley, M. E.; Cohen, S. B.; Madar, D. J. J. Am. Chem. Soc. 1997, 119, 6072-6094.
23. Fleck, A. E.; Hobart, J. A.; Morrow, G. W. Synth. Commun. 1992, 22, 179-187.
24. Reported experimental procedure did not work in our hands. However, we were able to make 4.2 (75%) by a modified workup, while a modified method gave 92% yield: PhIO was added to a solution of 4.1 and then TsOH was added. The mixture was concentrated to a small volume (not to dryness) and then chromatographed over silica gel, using MeOH-EtOAc-hexane (the presence of MeOH was essential).
25. Oxidation of 4.1 was examined as a model for 33.
26. Garegg, P. J.; Samuelson, B. J. Chem. Soc., Chem. Commun. 1979, 978-980.
27. Toluene solutions of tributyltin hydride (0.07-0.12 M) and AIBN (0.005-0.0110 M, 0.1 equiv) were added over 3-5 h to a hot (85°C) solution (0.035 M) of the substrate, and heating was continued for an arbitrary period of 1-10 h after the addition.
28. In the absence of molecular sieves, with compound 11b, we did observe the undesired pathway as a minor pathway (we have not tested other compounds under the same conditions or attempted to optimize this minor pathway). Conversion of 14b to 14c was arbitrarily done without molecular sieves.